摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

trimethyl-(3-trifluoromethoxyphenylethynyl)-silane | 866683-58-1

中文名称
——
中文别名
——
英文名称
trimethyl-(3-trifluoromethoxyphenylethynyl)-silane
英文别名
Benzene, 1-(trifluoromethoxy)-3-[2-(trimethylsilyl)ethynyl]-;trimethyl-[2-[3-(trifluoromethoxy)phenyl]ethynyl]silane
trimethyl-(3-trifluoromethoxyphenylethynyl)-silane化学式
CAS
866683-58-1
化学式
C12H13F3OSi
mdl
——
分子量
258.315
InChiKey
PSEDUYGGVFKWJX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    227.3±40.0 °C(Predicted)
  • 密度:
    1.12±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.81
  • 重原子数:
    17
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    9.2
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    电化学金催化 C−C 多重键的 1,2-双官能化**
    摘要:
    第一份关于电化学 Au I /Au III催化 C−C 多重键 1,2-双官能化的报告已经发表。这种无外部氧化剂的方法利用乙烯基-Au I到乙烯基-Au III络合物的阳极氧化来实现联烯酸酯的氧炔化,从而在未分裂的电池中获得炔取代的丁烯内酯。
    DOI:
    10.1002/anie.202308636
  • 作为产物:
    描述:
    3-三氟甲氧基溴苯三甲基乙炔基硅 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 三乙胺 作用下, 以 乙酸乙酯 为溶剂, 反应 18.0h, 以100%的产率得到trimethyl-(3-trifluoromethoxyphenylethynyl)-silane
    参考文献:
    名称:
    [EN] PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS
    [FR] DERIVES DE PYRIDYLE ET LEUR UTILISATION EN TANT QU'ANTAGONISTES DU RECEPTEUR DE MGLU5
    摘要:
    本发明涉及公式(I)的吡啶衍生物作为mGlu5受体拮抗剂。因此,这些化合物可能对通过拮抗mGlu5受体而得到缓解的疾病的治疗或预防有用,其中Ar是苯基或萘基,每种基可能被一个或多个C1-C4烷基,C1-C4烷氧基,C1-C5酰基,卤素,氨基,硝基,氰基,羟基,C1-C5酰胺基,C1-C4烷基磺酰胺基,单-,二-或三氟代的C1-C3烷基,取代基可能相同也可能不同,并且可能带有CONH2,CONHCH3,CON(CH3)2,CO2H,CO2CH3,OCF3,CH2NHCOCH3,CH2NH2,CH2N(CH3)2,CH2CN,CH2OH,CH2NHSO2CH3,CH2N(CH3)(CH2)2CN,CH2N(CH3)CH(CH3)2,CH2NHCH(CH3)2,CH2NH(CH2)2CH3,CH2NHCO2R4,CH2NHCH2CH3,CH2NHCH3 NHCOC(CH3)2或N(S(O)2CH3)2取代基;R1是氢,卤素,R4,CN,C(NOH)R3,C(NO-R4)R3,(CH)2CO2R4,(CH2)nOR3,COR3,CF3,SR4,S(O)R4,S(O)2R4,COCH2CO2R3,NHSO2R4,NHCOR3,C(NOR3)NH2,CH2OCOR3,(CH2)nNH2,CON(CH3)2(CH2)nNHCO2R4,CO2R3,CONH2,CSNH2,C(NH)NHOR3,(CH2)nN(CH3)2或CONHNHCOR3;R2是1,2-乙烯二基或1,2-乙炔二基;R3是氢或C1-C4烷基;R4是C1-C4烷基;n为0,1,2,3或4;或其药学上可接受的盐,或其N-氧化物。
    公开号:
    WO2005094822A1
点击查看最新优质反应信息

文献信息

  • Nickel-Catalyzed Enantioselective α-Alkenylation of <i>N</i>-Sulfonyl Amines: Modular Access to Chiral α-Branched Amines
    作者:Lun Li、Yu-Cheng Liu、Hang Shi
    DOI:10.1021/jacs.1c00622
    日期:2021.3.24
    α-branched amines are common structural motifs in functional materials, pharmaceuticals, and chiral catalysts. Therefore, developing efficient methods for preparing compounds with these privileged scaffolds is an important endeavor in synthetic chemistry. Herein, we describe an atom-economical, modular method for a nickel-catalyzed enantioselective α-alkenylation of readily available linear N-sulfonyl amines
    手性α-支化胺是功能材料、药物和手性催化剂中常见的结构基序。因此,开发用于制备具有这些特权支架的化合物的有效方法是合成化学中的一项重要努力。在这里,我们描述了一种原子经济的模块化方法,用于镍催化的线性N 的对映选择性 α-烯基化-磺胺与炔烃可提供多种烯丙基胺,无需外源性氧化剂、还原剂或活化剂。该方法为构建手性α-支化胺以及α-氨基酰胺和β-氨基醇等衍生物提供了一个平台,这些衍生物可以方便地从新引入的烯烃中获得。鉴于该方法的通用性、多功能性和高原子经济性,我们预计它将具有广泛的合成效用。
  • Ligand-Promoted Alkynylation of Aryl Ketones: A Practical Tool for Structural Diversity in Drugs and Natural Products
    作者:Hui Xu、Biao Ma、Zunyun Fu、Han-Yuan Li、Xing Wang、Zhen-Yu Wang、Ling-Jun Li、Tai-Jin Cheng、Mingyue Zheng、Hui-Xiong Dai
    DOI:10.1021/acscatal.0c05372
    日期:2021.2.5
    electrophiles via Ar–C(O) cleavage remains a challenging yet highly desirable transformation in Sonogashira-type coupling. Herein, we report a palladium-catalyzed ligand-promoted alkynylation of unstrained aryl ketones. The protocol allows the alkynylation to be carried out in a one-pot procedure with broad functional-group tolerance and substrate scope. The potential applications of this protocol
    通过Ar–C(O)裂解将众多芳基酮转化为芳基亲电体,在Sonogashira型偶联中仍然是具有挑战性但非常理想的转化。在本文中,我们报道了钯催化的配体促进的未应变芳基酮的炔基化反应。该协议允许炔基化反应以一锅法进行,具有宽泛的官能团耐受性和底物范围。该协议在药物发现和化学生物学中的潜在应用通过许多药物和天然产物的后期多样化进一步证明。更重要的是,可以通过酮的连续炔基化连接衍生自药物和天然产物的两个不同的生物学重要片段。与常规Sonogashira反应中的芳基卤化物不同,配体促进的ipso -Ar–C(O)炔基化作用使邻位C–H活化。
  • Pyridyl Derivatives and Their Use as Mglu5 Antagonists
    申请人:Agejas-Chicharro Francisco Javier
    公开号:US20080194647A1
    公开(公告)日:2008-08-14
    The present invention is directed toward pyridyl derivatives of formula (I) as antagonists of the mGlu5 receptor. As such the compounds may be useful for treatment or prevention of disorders remedied by antagonism of the mGlu5 receptor, wherein Ar is phenyl or napthyl each of which may be substituted by one or more C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 5 acyl, halo, amino, nitro, cyano, hydroxy, C 1 -C 5 acylamino, C 1 -C 4 alkylsulfonylamino, mono-, di- or trifluorinated C 1 -C 3 alkyl, substituents which may be the same or different and may bear a CONH 2 , CONHCH 3 , CON(CH 3 ) 2 , CO 2 H, CO 2 CH 3 , OCF 3 , CH 2 NHCOCH 3 , CH 2 NH 2 , CH 2 N(CH 3 ) 2 , CH 2 CN, CH 2 OH, CH 2 NHSO 2 CH 3 , CH 2 N(CH 3 )(CH 2 ) 2 CN, CH 2 N(CH 3 )CH(CH 3 ) 2 , CH 2 NHCH(CH 3 ) 2 , CH 2 NH(CH 2 ) 2 CH 3 , CH 2 NHCO 2 R 4 , CH 2 NHCH 2 CH 3 , CH 2 NHCH 3 NHCOC(CH 3 ) 2 , or N(S(O) 2 CH 3 ) 2 substituent; R 1 is hydrogen, halo, R 4 , CN, C(NOH)R 3 , C(NO—R 4 )R 3 , (CH) 2 CO 2 R 4 , (CH 2 ) n OR 3 , COR 3 , CF 3 , SR 4 , S(O)R 4 , S(O) 2 R 4 , COCH 2 CO 2 R 3 , NHSO 2 R 4 , NHCOR 3 , C(NOR 3 )NH 2 , CH 2 OCOR 3 , (CH 2 ) n NH 2 , CON(CH 3 ) 2 (CH 2 ) n NHCO 2 R 4 , CO 2 R 3 , CONH 2 , CSNH 2 , C(NH)NHOR 3 , (CH 2 ) n N(CH 3 ) 2 , or CONHNHCOR 3 ; R 2 is 1,2-ethenediyl or 1,2-ethynediyl; R 3 is hydrogen or C 1 -C 4 alkyl; R 4 is C 1 -C 4 alkyl; and n is 0, 1, 2, 3 or 4; or a pharmaceutically acceptable salt thereof, or an N-oxide thereof.
    本发明涉及公式(I)的吡啶衍生物,作为mGlu5受体的拮抗剂。因此,这些化合物可能对治疗或预防通过拮抗mGlu5受体来治疗的疾病有用,其中Ar是苯基或萘基,可以被一个或多个C1-C4烷基,C1-C4烷氧基,C1-C5酰基,卤素,氨基,硝基,氰基,羟基,C1-C5酰基氨基,C1-C4烷基磺酰氨基,单,二或三氟代C1-C3烷基,取代基可以相同或不同,并且可能带有CONH2,CONHCH3,CON(CH3)2,CO2H,CO2CH3,OCF3,CH2NHCOCH3,CH2NH2,CH2N(CH3)2,CH2CN,CH2OH,CH2NHSO2CH3,CH2N(CH3)(CH2)2CN,CH2N(CH3)CH(CH3)2,CH2NHCH(CH3)2,CH2NH(CH2)2CH3,CH2NHCO2R4,CH2NHCH2CH3,CH2NHCH3NHCOC(CH3)2或N(S(O)2CH3)2取代基;R1是氢,卤素,R4,CN,C(NOH)R3,C(NO—R4)R3,(CH)2CO2R4,(CH2)nOR3,COR3,CF3,SR4,S(O)R4,S(O)2R4,COCH2CO2R3,NHSO2R4,NHCOR3,C(NOR3)NH2,CH2OCOR3,(CH2)nNH2,CON(CH3)2(CH2)nNHCO2R4,CO2R3,CONH2,CSNH2,C(NH)NHOR3,(CH2)nN(CH3)2或CONHNHCOR3;R2是1,2-乙烯基或1,2-乙炔基;R3是氢或C1-C4烷基;R4是C1-C4烷基;n为0、1、2、3或4;或其药学上可接受的盐或其N-氧化物。
  • Pyridyl derivatives and their use as mGlu5 antagonists
    申请人:Eli Lilly and Company
    公开号:US07915424B2
    公开(公告)日:2011-03-29
    The present invention is directed toward pyridyl derivatives of formula (I) as antagonists of the mGlu5 receptor. As such the compounds may be useful for treatment or prevention of disorders remedied by antagonism of the mGlu5 receptor, wherein Ar is phenyl or napthyl each of which may be substituted by one or more C1-C4 alkyl, C1-C4 alkoxy, C1-C5 acyl, halo, amino, nitro, cyano, hydroxy, C1-C5 acylamino, C1-C4 alkylsulfonylamino, mono-, di- or trifluorinated C1-C3 alkyl, substituents which may be the same or different and may bear a CONH2, CONHCH3, CON(CH3)2, CO2H, CO2CH3, OCF3, CH2NHCOCH3, CH2NH2, CH2N(CH3)2, CH2CN, CH2OH, CH2NHSO2CH3, CH2N(CH3)(CH2)2 CN, CH2N(CH3)CH(CH3)2, CH2NHCH(CH3)2, CH2NH(CH2)2CH3, CH2NHCO2R4, CH2NHCH2CH3, CH2NHCH3 NHCOC(CH3)2, or N(S(O)2CH3)2 substituent; R1 is hydrogen, halo, R4, CN, C(NOH)R3, C(NO—R4)R3, (CH)2CO2R4, (CH2)n OR3, COR3, CF3, SR4, S(O)R4, S(O)2R4, COCH2CO2R3, NHSO2R4, NHCOR3, C(NOR3)NH2, CH2OCOR3, (CH2)nNH2, CON(CH3)2 (CH2)nNHCO2R4, CO2R3, CONH2, CSNH2, C(NH)NHOR3, (CH2)nN(CH3)2, or CONHNHCOR3; R2 is 1,2-ethenediyl or 1,2-ethynediyl; R3 is hydrogen or C1-C4 alkyl; R4 is C1-C4 alkyl; and n is 0, 1, 2, 3 or 4; or a pharmaceutically acceptable salt thereof, or an N-oxide thereof.
    本发明涉及公式(I)的吡啶衍生物作为mGlu5受体拮抗剂。因此,这些化合物可能有用于治疗或预防通过mGlu5受体拮抗疗法治疗的疾病,其中Ar为苯基或萘基,可以被一个或多个C1-C4烷基,C1-C4烷氧基,C1-C5酰基,卤素,氨基,硝基,氰基,羟基,C1-C5酰胺基,C1-C4烷基磺酰胺基,单,二或三氟化C1-C3烷基,取代基可以相同或不同,可以承载CONH2,CONHCH3,CON(CH3)2,CO2H,CO2CH3,OCF3,CH2NHCOCH3,CH2NH2,CH2N(CH3)2,CH2CN,CH2OH,CH2NHSO2CH3,CH2N(CH3)(CH2)2CN,CH2N(CH3)CH(CH3)2,CH2NHCH(CH3)2,CH2NH(CH2)2CH3,CH2NHCO2R4,CH2NHCH2CH3,CH2NHCH3,NHCOC(CH3)2或N(S(O)2CH3)2取代基;R1为氢,卤素,R4,CN,C(NOH)R3,C(NO—R4)R3,(CH)2CO2R4,(CH2)n OR3,COR3,CF3,SR4,S(O)R4,S(O)2R4,COCH2CO2R3,NHSO2R4,NHCOR3,C(NOR3)NH2,CH2OCOR3,(CH2)nNH2,CON(CH3)2(CH2)nNHCO2R4,CO2R3,CONH2,CSNH2,C(NH)NHOR3,(CH2)nN(CH3)2或CONHNHCOR3;R2为1,2-乙烯基或1,2-乙炔基;R3为氢或C1-C4烷基;R4为C1-C4烷基;n为0、1、2、3或4;或其药学上可接受的盐,或其N-氧化物。
  • [EN] PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE PYRIDYLE ET LEUR UTILISATION EN TANT QU'ANTAGONISTES DU RECEPTEUR DE MGLU5
    申请人:LILLY CO ELI
    公开号:WO2005094822A1
    公开(公告)日:2005-10-13
    The present invention is directed toward pyridyl derivatives of formula (I) as antagonists of the mGlu5 receptor. As such the compounds may be useful for treatment or prevention of disorders remedied by antagonism of the mGlu5 receptor, wherein Ar is phenyl or napthyl each of which may be substituted by one or more C1-C4 alkyl, C1-C4 alkoxy, C1-C5 acyl, halo, amino, nitro, cyano, hydroxy, C1-C5 acylamino, C1-C4 alkylsulfonylamino, mono-, di- or trifluorinated C1-C3 alkyl, substituents which may be the same or different and may bear a CONH2, CONHCH3, CON(CH3)2, CO2H, CO2CH3, OCF3, CH2NHCOCH3, CH2NH2, CH2N(CH3)2, CH2CN, CH2OH, CH2NHSO2CH3, CH2N(CH3)(CH2)2 CN, CH2N(CH3)CH(CH3)2, CH2NHCH(CH3)2, CH2NH(CH2)2CH3, CH2NHCO2R4, CH2NHCH2CH3, CH2NHCH3 NHCOC(CH3)2, or N(S(O)2CH3)2 substituent; R1 is hydrogen, halo, R4, CN, C(NOH)R3, C(NO-R4)R3, (CH)2CO2R4 , (CH2)n OR3 , COR3 , CF3, SR4 , S(O)R4, S(O)2R4, COCH2CO2R3 , NHSO2R4 , NHCOR3, C(NOR3)NH2, CH2OCOR3 , (CH2)n NH2, CON(CH3)2 (CH2)nNHCO2R4 , CO2R3, CONH2, CSNH2, C(NH)NHOR3, (CH2)nN(CH3)2, or CONHNHCOR3; R2 is 1,2-ethenediyl or 1,2-ethynediyl; R3 is hydrogen or C1-C4 alkyl; R4 is C1-C4 alkyl; and n is 0, 1, 2,3 or 4; or a pharmaceutically acceptable salt thereof, or an N-oxide thereof.
    本发明涉及公式(I)的吡啶衍生物作为mGlu5受体拮抗剂。因此,这些化合物可能对通过拮抗mGlu5受体而得到缓解的疾病的治疗或预防有用,其中Ar是苯基或萘基,每种基可能被一个或多个C1-C4烷基,C1-C4烷氧基,C1-C5酰基,卤素,氨基,硝基,氰基,羟基,C1-C5酰胺基,C1-C4烷基磺酰胺基,单-,二-或三氟代的C1-C3烷基,取代基可能相同也可能不同,并且可能带有CONH2,CONHCH3,CON(CH3)2,CO2H,CO2CH3,OCF3,CH2NHCOCH3,CH2NH2,CH2N(CH3)2,CH2CN,CH2OH,CH2NHSO2CH3,CH2N(CH3)(CH2)2CN,CH2N(CH3)CH(CH3)2,CH2NHCH(CH3)2,CH2NH(CH2)2CH3,CH2NHCO2R4,CH2NHCH2CH3,CH2NHCH3 NHCOC(CH3)2或N(S(O)2CH3)2取代基;R1是氢,卤素,R4,CN,C(NOH)R3,C(NO-R4)R3,(CH)2CO2R4,(CH2)nOR3,COR3,CF3,SR4,S(O)R4,S(O)2R4,COCH2CO2R3,NHSO2R4,NHCOR3,C(NOR3)NH2,CH2OCOR3,(CH2)nNH2,CON(CH3)2(CH2)nNHCO2R4,CO2R3,CONH2,CSNH2,C(NH)NHOR3,(CH2)nN(CH3)2或CONHNHCOR3;R2是1,2-乙烯二基或1,2-乙炔二基;R3是氢或C1-C4烷基;R4是C1-C4烷基;n为0,1,2,3或4;或其药学上可接受的盐,或其N-氧化物。
查看更多